{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:03:47Z","timestamp":1792091027414,"version":"4.4.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Journal Armed Forces India"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.mjafi.2022.02.006","type":"journal-article","created":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T17:39:11Z","timestamp":1650389951000},"page":"S119-S124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"S1","title":["Therapeutic drug monitoring of Amikacin in hospitalized patients: A pilot study"],"prefix":"10.1016","volume":"79","author":[{"given":"Sanjay","family":"Jaiswal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.P.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4141-232X","authenticated-orcid":false,"given":"Prafull","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.mjafi.2022.02.006_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3904\/kjim.2009.24.1.1","article-title":"Overview of therapeutic drug monitoring","volume":"24","author":"Kang","year":"2009","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.mjafi.2022.02.006_bib2","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3390\/pharmaceutics13020264","article-title":"Evaluation of current Amikacin dosing recommendations and development of an interactive nomogram: the role of albumin","volume":"13","author":"P\u00e9rez-Blanco","year":"2021","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.mjafi.2022.02.006_bib3","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/jac\/dkx427","article-title":"MIC-based dose adjustment: facts and fables","volume":"73","author":"Mouton","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mjafi.2022.02.006_bib4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1365-2125.1999.00850.x","article-title":"The therapeutic monitoring of antimicrobial agents","volume":"47","author":"Begg","year":"1999","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.mjafi.2022.02.006_bib5","first-page":"1811","article-title":"Aminoglycosides: a practical review","volume":"58","author":"Gonzalez","year":"1998","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.mjafi.2022.02.006_bib6","series-title":"Basic & Clinical Pharmacology","first-page":"826","article-title":"Aminoglycosides & spectinomycin","author":"Beauduy","year":"2018"},{"key":"10.1016\/j.mjafi.2022.02.006_bib7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/infdis\/155.1.93","article-title":"Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration","volume":"155","author":"Moore","year":"1987","journal-title":"J Infect Dis"},{"key":"10.1016\/j.mjafi.2022.02.006_bib8","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13613-020-00685-5","article-title":"Amikacin pharmacokinetic\/pharmacodynamic in intensive care unit: a prospective database","volume":"10","author":"Logre","year":"2020","journal-title":"Ann Intensive Care"},{"issue":"4","key":"10.1016\/j.mjafi.2022.02.006_bib9","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1128\/AAC.42.4.849","article-title":"Population pharmacokinetic study of Amikacin administered once or twice daily to febrile, severely neutropenic adults","volume":"42","author":"Tod","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.mjafi.2022.02.006_bib10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s40268-016-0165-5","article-title":"Evaluation of Amikacin pharmacokinetics and pharmacodynamics for optimal initial dosing regimen","volume":"17","author":"Kato","year":"2017","journal-title":"Drugs R"},{"key":"10.1016\/j.mjafi.2022.02.006_bib11","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2147\/IDR.S150839","article-title":"High-dose Amikacin for achieving serum target levels in critically ill elderly patients","volume":"11","author":"Sadeghi","year":"2018","journal-title":"Infect Drug Resist"},{"issue":"3","key":"10.1016\/j.mjafi.2022.02.006_bib12","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4103\/0976-0105.183260","article-title":"Therapeutic monitoring of Amikacin and gentamicin in critically and noncritically ill patients","volume":"7","author":"Kova\u010devi\u0107","year":"2016","journal-title":"J Basic Clin Pharm"},{"issue":"suppl 1","key":"10.1016\/j.mjafi.2022.02.006_bib13","first-page":"A74","article-title":"4CPS-071 Therapeutic drug monitoring and safety of high-dose Amikacin in critically ill patients","volume":"25","author":"Barcelo","year":"2018","journal-title":"Eur J Hosp Pharm"},{"issue":"10","key":"10.1016\/j.mjafi.2022.02.006_bib14","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1093\/jac\/dkw250","article-title":"(BSAC Working Party on Therapeutic Drug Monitoring). Amikacin use and therapeutic drug monitoring in adults: do dose regimens and drug exposures affect either outcome or adverse events? A systematic review","volume":"71","author":"Jenkins","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.mjafi.2022.02.006_bib15","first-page":"227","article-title":"Optimal Amikacin levels for patients with sepsis in intensive care unit of cipto mangunkusumo hospital, Jakarta, Indonesia","volume":"49","author":"Aliska","year":"2017","journal-title":"Acta Med Indones"},{"key":"10.1016\/j.mjafi.2022.02.006_bib16","first-page":"3184","volume":"vol. 2","author":"Dollery","year":"1998"},{"issue":"1-2","key":"10.1016\/j.mjafi.2022.02.006_bib17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0378-4347(00)00133-X","article-title":"Current methodologies for the analysis of aminoglycosides","volume":"747","author":"Stead","year":"2000","journal-title":"J Chromatogr B Biomed Sci Appl"},{"issue":"3","key":"10.1016\/j.mjafi.2022.02.006_bib18","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0002-9343(02)01476-6","article-title":"Pharmacokinetic dosing of aminoglycosides: a controlled trial","volume":"114","author":"Bartal","year":"2003","journal-title":"Am J Med"},{"key":"10.1016\/j.mjafi.2022.02.006_bib19","series-title":"Treatment Guidelines for Antimicrobial Use in Common Syndromes","year":"2019"},{"key":"10.1016\/j.mjafi.2022.02.006_bib20","series-title":"National Formulary of India","first-page":"960","year":"2016"},{"issue":"4","key":"10.1016\/j.mjafi.2022.02.006_bib21","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1128\/AAC.34.4.614","article-title":"Determination of optimal dosage regimen for Amikacin in healthy volunteers by study of pharmacokinetics and bactericidal activity","volume":"34","author":"Garraffo","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mjafi.2022.02.006_bib22","series-title":"Martindale: The Complete Drug Reference","first-page":"4142","author":"Sweetman","year":"2011"},{"issue":"1","key":"10.1016\/j.mjafi.2022.02.006_bib23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2125.2011.04080.x","article-title":"Therapeutic drug monitoring of antimicrobials","volume":"73","author":"Roberts","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.mjafi.2022.02.006_bib24","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jiac.2020.09.033","article-title":"A meta-analysis of the target trough concentration of gentamicin and Amikacin for reducing the risk of nephrotoxicity","volume":"27","author":"Yamada","year":"2021","journal-title":"J Infect Chemother"}],"container-title":["Medical Journal Armed Forces India"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0377123722000223?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0377123722000223?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T11:52:20Z","timestamp":1759837940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0377123722000223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":24,"alternative-id":["S0377123722000223"],"URL":"https:\/\/doi.org\/10.1016\/j.mjafi.2022.02.006","relation":{},"ISSN":["0377-1237"],"issn-type":[{"value":"0377-1237","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic drug monitoring of Amikacin in hospitalized patients: A pilot study","name":"articletitle","label":"Article Title"},{"value":"Medical Journal Armed Forces India","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mjafi.2022.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Director General, Armed Forces Medical Services. Published by Elsevier, a division of RELX India Pvt. Ltd.","name":"copyright","label":"Copyright"}]}}